Athersys Book Value 2011-2026 | ATHX

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Athersys

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
60.2 M	31.4 M	23.3 M	43.1 M	23.4 M	11.2 M	19.7 M	20.9 M	19.8 M	20.2 M	7.3 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
60.2 M	7.3 M	25.5 M

Quarterly Book Value Athersys

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
7.43 M	10.5 M	21.6 M	27.7 M	35.5 M	35.2 M	45 M	60.2 M	72.1 M	73.3 M	72.3 M	59.7 M	59.7 M	59.7 M	59.7 M	41.7 M	41.7 M	41.7 M	41.7 M	61.7 M	61.7 M	61.7 M	61.7 M	33.6 M	33.6 M	33.6 M	33.6 M	19.1 M	19.1 M	19.1 M	19.1 M	25.1 M	25.1 M	25.1 M	25.1 M	28.7 M	28.7 M	28.7 M	28.7 M	34.2 M	34.2 M	34.2 M	34.2 M	27.6 M	27.6 M	27.6 M	27.6 M	15.7 M	15.7 M	15.7 M	15.7 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
73.3 M	7.43 M	36.3 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	5.1 M	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Happiness Biotech Group Limited HAPP	29 M	-	1.35 %	$ 17.8 M	China
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
Coherus BioSciences CHRS	61 M	$ 1.61	-2.73 %	$ 189 M	USA
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Celldex Therapeutics CLDX	527 M	$ 31.72	0.05 %	$ 2.11 B	USA
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
BioNTech SE BNTX	19.2 B	$ 96.94	3.75 %	$ 23.4 B	Germany
AstraZeneca PLC AZN	48.7 B	-	-	$ 96.9 B	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	27.8 M	-	-	$ 269 M	USA
CRISPR Therapeutics AG CRSP	1.92 B	$ 55.72	-1.17 %	$ 5.01 B	Schweiz
BiondVax Pharmaceuticals Ltd. BVXV	99.6 M	-	0.74 %	$ 768 M	Israel
Compugen Ltd. CGEN	157 M	$ 2.69	-3.24 %	$ 251 M	Israel
Abcam plc ABCM	727 M	-	-	$ 4.9 B	Britain
Galera Therapeutics GRTX	6.55 M	-	-32.59 %	$ 7.61 M	USA
Midatech Pharma plc MTP	11.4 M	-	-18.52 %	$ 27.3 M	Britain
Enlivex Therapeutics Ltd. ENLV	1.93 B	$ 0.82	6.92 %	$ 37.5 M	Israel
Affimed N.V. AFMD	97.2 M	-	-34.95 %	$ 21.5 M	Germany
Esperion Therapeutics ESPR	-302 M	$ 3.14	0.16 %	$ 653 M	USA
Eton Pharmaceuticals ETON	26.2 M	$ 30.72	-3.58 %	$ 827 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Forte Biosciences FBRX	61 M	$ 19.3	-7.08 %	$ 250 M	USA
Checkmate Pharmaceuticals CMPI	69.5 M	-	-	$ 231 M	USA
Celyad Oncology SA CYAD	19.7 M	-	-	$ 12.5 M	Belgium
Berkeley Lights BLI	142 M	-	-7.31 %	$ 87 M	USA
Galectin Therapeutics GALT	-126 M	$ 2.54	-1.17 %	$ 162 M	USA
Generation Bio Co. GBIO	86.2 M	-	-	$ 344 M	USA
IMV IMV	-6.6 M	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Grifols, S.A. GRFS	8.61 B	$ 7.93	-0.63 %	$ 5.39 B	Spain
Cyclacel Pharmaceuticals CYCCP	6.84 M	-	-4.36 %	$ 27 M	USA
Freeline Therapeutics Holdings plc FRLN	52.4 M	-	-	$ 384 M	Britain
Gracell Biotechnologies GRCL	1.38 B	-	-	$ 3.37 B	China
Heron Therapeutics HRTX	14.3 M	$ 0.87	-2.33 %	$ 145 M	USA
ImmuCell Corporation ICCC	27.1 M	$ 10.11	2.12 %	$ 91.3 M	USA
Anika Therapeutics ANIK	190 M	$ 14.71	-1.28 %	$ 211 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	3.84 M	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	69.4 M	-	1.93 %	$ 17.4 M	USA
Can-Fite BioPharma Ltd. CANF	9.51 M	$ 3.38	-1.46 %	$ 5.56 M	Israel
Aptose Biosciences APTO	-27.2 M	-	-45.71 %	$ 1.2 M	Canada